Antharis Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Series A
- Investors
-
3
Antharis Therapeutics General Information
Description
Operator of a multinational biopharmaceutical company intended to develop new treatments for cancer and inflammatory diseases. The company utilizes next-generation therapeutic monoclonal antibodies and antibody-drug conjugates to treat unmet medical needs, enabling patients with serious illnesses to live healthy and long lives.
Contact Information
Website
www.antharistherapeutics.comCorporate Office
- 6370 Nancy Ridge Drive
- Suite 112
- San Diego, CA 92121
- United States
Corporate Office
- 6370 Nancy Ridge Drive
- Suite 112
- San Diego, CA 92121
- United States
Antharis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 14-Jul-2022 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 01-May-2020 | Completed | Stealth |
Antharis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Antharis Therapeutics Patents
Antharis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260115303-A1 | Cdh17-binding antibodies and methods of use thereof | Pending | 25-Oct-2024 | ||
| WO-2026090578-A1 | Cdh17-binding antibodies and methods of use thereof | Pending | 25-Oct-2024 | ||
| US-20260159608-A1 | Flt3-binding antibodies and methods of use thereof | Pending | 25-Oct-2024 | ||
| WO-2026090567-A1 | Flt3-binding antibodies and methods of use thereof | Pending | 25-Oct-2024 | ||
| US-20260035466-A1 | Vista-binding antibodies and methods of use thereof | Pending | 01-Aug-2024 | C07K16/2827 |
Antharis Therapeutics Signals
Antharis Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Yazbeck & Co. | Venture Capital | Minority | ||
| Fuse Capital (Private Equity) | Venture Capital | Minority | ||
| iBionext | Accelerator/Incubator | Minority |
Antharis Therapeutics Acquisitions (2)
Antharis Therapeutics’s most recent deal was a Merger/Acquisition with Galileo Biotech. The deal was made on 23-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Galileo Biotech | 23-Aug-2023 | Merger/Acquisition | Biotechnology | ||
| Cassyni Biopharma | 14-Jul-2022 | Merger/Acquisition | Biotechnology |
Antharis Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Galileo Biotech | Rio de Janeiro, Brazil | 2015 |
Antharis Therapeutics FAQs
-
When was Antharis Therapeutics founded?
Antharis Therapeutics was founded in 2020.
-
Where is Antharis Therapeutics headquartered?
Antharis Therapeutics is headquartered in San Diego, CA.
-
What is the size of Antharis Therapeutics?
Antharis Therapeutics has 17 total employees.
-
What industry is Antharis Therapeutics in?
Antharis Therapeutics’s primary industry is Drug Discovery.
-
Is Antharis Therapeutics a private or public company?
Antharis Therapeutics is a Private company.
-
What is the current valuation of Antharis Therapeutics?
The current valuation of Antharis Therapeutics is .
-
What is Antharis Therapeutics’s current revenue?
The current revenue for Antharis Therapeutics is .
-
How much funding has Antharis Therapeutics raised over time?
Antharis Therapeutics has raised $5.2M.
-
Who are Antharis Therapeutics’s investors?
Yazbeck & Co., Fuse Capital (Private Equity), and iBionext have invested in Antharis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process